The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti-epithelial cell-adhesion molecule x anti-CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascites secondary t...

Descripción completa

Detalles Bibliográficos
Autores principales: Heiss, Markus M, Murawa, Pawel, Koralewski, Piotr, Kutarska, Elzbieta, Kolesnik, Olena O, Ivanchenko, Vladimir V, Dudnichenko, Alexander S, Aleknaviciene, Birute, Razbadauskas, Arturas, Gore, Martin, Ganea-Motan, Elena, Ciuleanu, Tudor, Wimberger, Pauline, Schmittel, Alexander, Schmalfeldt, Barbara, Burges, Alexander, Bokemeyer, Carsten, Lindhofer, Horst, Lahr, Angelika, Parsons, Simon L
Formato: Texto
Lenguaje:English
Publicado: Wiley Subscription Services, Inc., A Wiley Company 2010
Materias:
Cancer Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958458/
https://www.ncbi.nlm.nih.gov/pubmed/20473913
http://dx.doi.org/10.1002/ijc.25423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958458/
https://www.ncbi.nlm.nih.gov/pubmed/20473913
http://dx.doi.org/10.1002/ijc.25423

Ejemplares similares